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Abstract
Leprosy is an important health problem in Brazil despite extensive use of multidrug therapy. The nasal mucosa is the preferential
site of entry and exit of Mycobacterium leprae, and although lesions have been found in the oral mucosa, its potential involvement
in the transmission of leprosy bacilli has never been investigated. We investigated the presence of the M. leprae DNA in buccal
swabs of leprosy patients (334) and household contacts (1288) through polymerase chain reaction (PCR), and correlated this with
clinical and laboratorial evaluations. The overall positivity for patients and contacts was 18.26% and 6.83%, respectively. Subclinical
infection among contacts was considered when PCR and anti-PGL-1 ELISA presented positive results. This study provides evidence
that the oral mucosa may be a secondary site of M. leprae transmission and infection, and contacts with bacillary DNA may be
actively involved in transmission. We have also shown that bacilli DNA is more frequently found in the oral mucosa of PB
patients. Our ﬁndings have great epidemiological relevance and indicate an additional strategy for leprosy control programmes and
dental clinics.
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Introduction
Leprosy is considered to be a public health problem in Brazil,
which has the second largest number of cases in the world,
with a prevalence of 41 817 cases at the beginning of 2009
and an incidence of 38 914 in 2008 [1]. It is a spectral dis-
ease and variation in clinical forms is related to distinct
immunological patterns [2]. Among the polar forms, tubercu-
loid (TT) and lepromatous (LL), there are immunologically
unstable forms: borderline-tuberculoid (BT), borderline-bor-
derline (BB) and borderline-lepromatous (BL) [3].
The source of infection is a patient with a non-treated
high bacterial load of the multibacillary form (MB) [4], but
persons infected who display no clinical manifestation of the
disease but have the presence of bacillus in their nasal
mucosa may be involved in subclinical transmission [5]. The
nasal mucosa is the preferential site for entry and exit of the
Mycobacterium leprae [6] and the initial infection occurs in
the upper airways [7].
However, involvement of the oral cavity is rarely reported
and oral lesions are described in patients with lepromatous
leprosy, and in a few cases of patients with tuberculoid and
borderline forms [8–10]. The mouth may act as a transmis-
sion source, with an important role in the production of
new cases. Because it is a contagious infectious disease, the
earlier the diagnosis and treatment, the greater the possibil-
ity of a favourable clinical course [11].
Mycobacterium leprae genomic regions have been detected
by PCR in oral mucosa biopsies of MB patients [12]. Similar
results were predicted for buccal swabs, but this study has
not been performed yet. Despite the ample epidemiological
distribution and leprosy being considered a public health
problem, few studies in the literature cover the relationship
of the oral cavity with the disease [10].
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Thus, this study had the objective of detecting M. leprae
DNA in buccal swabs of leprosy patients and household
contacts in order to determine the involvement of the oral
mucosa as a source of infection and transmission of bacilli.
Additionally, we have explored the possible implications of
these ﬁndings by associating the DNA detection with the
bacterial index (BI), anti-PGL-1 ELISA and the Mitsuda test,
which have been used as auxiliary tools in diagnosis and clas-
siﬁcation of clinical forms of leprosy patients and for moni-
toring of household contacts.
Cases and Methods
Treatment-naı¨ve patients with leprosy (334) and their house-
hold contacts (1288) seen at the National Reference Center
for Sanitary Dermatology and Leprosy of Uberlaˆndia, partici-
pated in the cross-sectional study approved by the Ethics in
Research Committee under # 099/2003, signed the informed
consent forms and authorized the collection of samples.
Patients were diagnosed and classiﬁed into TT, BT, BB, BL
and LL forms, according to Ridley–Jopling [2], based on
Bacterial Index (BI) of dermal swabs, histological analyses, BI
of skin lesion biopsies, and the Mitsuda intradermal test, to
evaluate cellular immunity to M. leprae, considering positive
values ‡4 mm [13]. To assess humoral response, the ELISA
serological test against the bacillus-speciﬁc antigen, PGL-1
(kindly donated by Dr John Spencer, Colorado State Univer-
sity), was performed, considering positive results with a cut-
off ‡1.1, as demonstrated elsewhere [14,15].
Patients received an operational classiﬁcation as paucibacil-
lary (PB) or multibacillary (MB). TT or BT forms with ﬁve or
less skin lesions and negative BI were considered PB. BT
forms with more than ﬁve skin lesions and/or a BI from zero
to two in the skin lesion were considered MB [16]. The
household contacts that resided or had resided with the
patient over the previous 5 years [17] submitted to the der-
mato-neurological examination, Mitsuda test and anti-PGL-1
ELISA assay to assure their health status.
DNA extraction and PCR
The collection of nasal swabs from patients and buccal
swabs from patients and contacts was carried out by
introducing small ﬂexible brushes, and swabbing the nasal
septum via both nasal fosses and the oral mucosa (mucosa
lining of the cheeks and lips). The stems with the material
were deposited in sterile tubes containing 500 lL of lysis
buffer (NaCl 400 mM, EDTA, 50 mM pH 8.0 and Tris–HCl
25 mM pH 8.0). Each sample was individually conditioned
in sterile microtubes and maintained at 4C until DNA
extraction. For the detection of M. leprae in samples, a
pair of primers [18] was used to amplify 130 bp fragments
of the RLEP M. leprae genomic region (Fig. 1), using stan-
dardized conditions for PCR reactions described elsewhere
[19].
Statistical analysis
Descriptive analyses were carried out for the data. The chi-
square test was used to evaluate differences in positivity
between samples from patients and contacts, and among clin-
ical forms. Pearson’s correlation coefﬁcient was employed
to determine the association among the results of anti-
PGL-1ELISA, the Mitsuda test and BI of skin lesions, consid-
ering p <0.05 as signiﬁcant.
(a) (b)
FIG. 1. Detection of Mycobacterium leprae DNA by PCR. (a) Quality of the total DNA extracted in buccal swab samples from patients with lep-
rosy visualized in agarose 0.8% gel and stained with ethidium bromide. (b) The positive detection of M. leprae DNA is demonstrated by the
ampliﬁcation of a 130 bp fragment of the RLEP3 genomic region: columns 1 (positive control), 3 and 6. Negative samples: columns 2, 4, 5, 7–10.
B: negative control; M-100 bp marker. Fragments of 200 bp observed in columns 1–10 correspond to the ampliﬁcation of the NRAMP1 gene as
the internal control.
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Results
The mean age of patients was 47.66 ± 16.14 years, with a
predominance of the male gender (206/334; 61.68%). The
most prevalent operational form of patients was the MB,
reaching 67.66% (226/334). For the clinical classiﬁcation, the
highest prevalence was in the borderline group, correspond-
ing to 67.66% (226/334), with a predominance of 38.32%
(128/334) of the BT form.
The positivity of laboratory assays, according to the clini-
cal classiﬁcation [2], is presented in Fig. 2. We observed a
strong positive correlation between anti-PGL-1 ELISA and BI
of the skin smears (r = 0.9763 and p 0.0044), anti-PGL-1
ELISA and BI of the skin biopsy (r = 0.9204 and p 0.0266)
and BI of the skin smears and BI of the skin biopsy
(r = 0.9423 and p 0.0165), and strong negative correlations
between the Mitsuda test and anti-PGL-1 ELISA (r = )0.9994
and p <0.0001), BI of the skin smears (r = )0.9711 and
p 0.0059) and BI of the skin biopsy (r = )0.9253 and
p 0.0242). Positivities of buccal swabs, skin smears, skin
biopsy and anti-PGL-1 ELISA tests increased towards the MB
forms, reaching 42.86% in buccal swabs in the LL form and
100% in the BL and LL forms in the other laboratory assays.
On the other hand, the Mitsuda test demonstrated 100%
positivity in the TT form, and was negative for all patients
with BL and LL forms.
DNA detection in buccal swabs of patients (Fig. 1) demon-
strated a positivity of 18.26% (61/334), varying from 13.16%
(5/38) in the TT form to 42.86% (30/70) in LL (Fig. 2). Signiﬁ-
cant differences of positivities were observed between LL vs.
TT (v2 = 15.746; p 0.0001), LL vs. BT (v2 = 21.457; p <
0.0001), LL vs. BB (v2 = 12.608; p 0.0006), and LL vs. BL
(v2 = 16.276; p <0.0001) forms.
Within the 334 buccal swab samples there were missing
data for other parameters, and only 290 nasal swab samples
were matched for the same patients, so correlation analysis
was performed only for patients who had paired data. PB
patients demonstrated 12.37% (12/97) positivity for M. le-
prae DNA detection in buccal swabs, and although almost
50% lower, it was not signiﬁcantly different from MB
patients, who demonstrated 20.21% (39/193) positivity
(v2 = 2.254; p 0.190). However, PB patients demonstrated
6.18% (6/97) positivity for buccal swabs when nasal swabs
were negative, while detection in nasal swabs when buccal
swabs were negative demonstrated a 3.09% (3/97) positivity
(v2 = 1.080; p 0.4821). Positive detection for PB patients in
both collection sites was 6.18% (6/97). Interestingly, among
MB patients detected using buccal swabs, only the BT-MB
and BB forms demonstrated positive results when nasal
swabs were negative (4.21%; 4/95). Evaluation of the posi-
tivity for nasal swabs when buccal swabs were negative
indicated that MB patients showed a two-fold positivity
(36.27%; 70/193) compared with that observed in both buc-
cal and nasal swabs (18.13%; 35/193) (v2 = 8.309; p 0.0065)
(Table 1).
The overall positivity of the bacillary DNA detection was
17.59% (51/290) in buccal and 39.31% (114/290) in nasal
swabs from patients (v2 = 11.588; p 0.0012). The positivity
of both collection sites has increased toward the LL pole,
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FIG. 2. Percentage of positivity (%) for bacterial index of skin smears and skin biopsies, Mitsuda test, serum anti-PGL1 ELISA and buccal swab in
leprosy patients and their distribution according to the clinical forms of Ridley and Jopling.
TABLE 1. Detection of Mycobacterium leprae DNA by PCR
in samples of buccal (B) and nasal (N) swabs of leprosy
patients according to the clinical forms
Clinical
forms
PCR
TotalB+N) B)N+ B+N+
n (%) n (%) n (%) n (%)
TT 2 (6.06) 0 (0.00) 3 (9.09) 33 (11.38)
BT–PB 4 (6.25) 3 (4.69) 3 (4.69) 64 (22.07)
BT–MB 1 (1.92) 2 (3.85) 1 (1.92) 52 (17.93)
BB 3 (6.98) 10 (23.26) 4 (9.30) 43 (14.83)
BL 0 (0.00) 25 (64.10) 4 (10.26) 39 (13.45)
LL 0 (0.00) 33 (55.93) 26 (44.07) 59 (20.34)
Total 10 (3.45) 73 (25.17) 41 (14.14) 290 (100)
TT, tuberculoid; LL, lepromatous; BT, borderline-tuberculoid; BB, borderline-
borderline; BL, borderline-lepromatous, MB, multibacillary.
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reaching 44.07% (26/59) in buccal swabs and 100% (59/59) in
nasal swabs (v2 = 77.643; p <0.0001).
Of all patients, 3.45% (10/290) demonstrated positive
results for buccal swabs and negative results for nasal swabs
(Table 1). A concomitant positivity for both PCR in buccal
swabs and anti-PGL-1 ELISA was observed in 13.2% (36/272)
of the patients. Positive DNA in buccal swabs and negative
Mitsuda tests were observed in 13.5% (35/260) of the
patients.
Among the 1288 household contacts, the mean age was
28.46 ± 19.3 years, and 55.9% (720/1288) were female. The
operational classiﬁcation of the index cases was predomi-
nantly MB (77.09%; 993/1288). The overall positivity for
detection of bacillary DNA in buccal swabs of contacts was
6.83% (88/1288), which was signiﬁcantly different from the
overall positivity of 18.26% (61/334) found in patients
(v2 = 5.207; p 0.0373).
Analysing the household contacts of PB and MB patients,
5.08% (15/295) and 7.35% (73/993) had positive buccal
swabs, respectively (v2 = 0.415; p 0.7187). Among the posi-
tive contacts for M. leprae DNA in buccal swabs, 21.67%
(13/60) displayed positive anti-PGL-1 ELISA, and 15% (12/80)
were negative for the Mitsuda test.
Discussion
This is the ﬁrst investigation that extensively covers the
molecular epidemiology of M. leprae in buccal swabs by
detecting bacillary DNA in leprosy patients and household
contacts, with additional comparisons with PCR results from
nasal swabs, and with stratiﬁcation of samples into clinical
forms of leprosy, and also taking into consideration the
humoral and cellular responses. The recruited patients came
from an area where leprosy was endemic, and there was a
greater prevalence of men, which agrees with previous stud-
ies that point to lifestyle and greater involvement in the
workforce as factors that increase the risk for men [4].
Regarding the operational classiﬁcation, the greater preva-
lence of MB patients also concurs with the literature [20].
We have also observed a predominance of the borderline
group, especially the BT form, similar to the African preva-
lence of leprosy, which is likely to reﬂect a genetic factor in
the capacity to express cell-mediated immunity to M. leprae
[3].
Our results showed that the humoral response, assessed
by the anti-PGL-1ELISA, is directly proportional to the bacil-
lary load, measured by the BI of the smears and the biopsy
of skin lesions [21,22], increasing as the spectrum is tra-
versed towards the LL pole, and inversely proportional to
the Mitsuda test, which is strongly positive in the TT pole,
corroborating the spectral classiﬁcation of the disease [2].
Regarding the PCR analysis of the buccal swabs, despite
the higher positivity in MB patients, the positivity rates of
M. leprae DNA in the oral cavity were similar in all clinical
forms of the disease, including the TT form, indicating that
they are carriers of the bacillus and that the mouth might
function as a route of initial and transitory infection for this
clinical form, which displayed negative BI in skin smears and
in skin biopsies. Additionally, the presence of M. leprae DNA
in the TT form might also contribute to the transmission of
the bacillus to household contacts.
In this investigation, we have also demonstrated that the
positivity rates of the nasal swabs in patients were greater
than buccal swabs in all clinical forms of the spectrum, with
the exception of the TT form, corroborating ﬁndings that
demonstrated the nasal mucosa as the preferential site for
entry and exit of M. leprae [19]. However, when patients
were stratiﬁed based on their individual or combined detec-
tion in nasal and buccal swabs, the M. leprae DNA was more
prevalent in buccal swabs of PB patients, while the bacilli
DNA was more frequently found in nasal swabs of MB
patients. This is the ﬁrst time that the oral mucosa has been
shown to be a more prevalent site in PB patients, and may
have important implications for transmission.
Furthermore, the observation of positive buccal swabs for
M. leprae DNA concurrent with negative nasal swabs from
patients may suggest that for some individuals the mouth may
act as the primary site of infection, and might also be involved
in bacilli dissemination through this route. The detection of
M. leprae DNA in buccal swabs of patients that also had posi-
tive anti-PGL-1 ELISA and negative Mitsuda tests, reinforces
the involvement of MB patients as a primary source of trans-
mission of the bacillus through the upper airways [3].
The three-fold difference in the overall positivity of DNA
detection in buccal swabs of patients compared with contacts
also suggests that the greatest source of infection and trans-
mission of M. leprae is non-treated patients. The greater prev-
alence of women and their mean age range among household
contacts may be explained by the greater number of adult
women who seek healthcare services when summoned for
surveillance programmes for contacts of leprosy patients [17].
The lack of a difference in M. leprae DNA detection in buc-
cal swabs of household contacts of PB and MB patients may
be explained by the presence of M. leprae DNA in the upper
airways of PB patients, which may also disseminate bacilli as it
occurs in MB patients, which was also demonstrated in this
investigation. This fact justiﬁes the two-fold increased risk of
household contacts acquiring leprosy in comparison to non-
contacts [4]. Moreover, it may be possible that contacts of PB
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and MB patients that live in areas where the disease is ende-
mic may also create opportunities for new contacts with the
bacilli [23].
Another important inference from the epidemiological
data from contacts, regarding those with detection of M. le-
prae DNA in buccal swabs and negative results for the anti-
PGL-1 ELISA, is the possibility that they are bacilli carriers
and a secondary source of transmission, contributing to its
dissemination; this may be due to the high pressure of bacil-
lary load from patients with whom they live, which creates a
highly infective environment before treatment, especially dur-
ing the initial phase of the disease [11,24]. However, in a
second phase, these healthy household contacts are not only
carriers of the bacillus in their oral cavity, but they also bear
a subclinical infection, presenting with concomitant positivity
of anti-PGL-1 ELISA in serum and DNA in buccal swabs, as
demonstrated in the present investigation, thus reinforcing
even further an active role in the transmission of the disease
[25–27].
The association of bacillary DNA in buccal swabs with
negative Mitsuda tests in contacts is an important combined
risk factor for acquiring leprosy, and these individuals may be
closely monitored, once a negative Mitsuda test alone con-
fers a six-fold higher risk of leprosy occurrence [11,24]. So,
a contact with a negative Mistuda test lacks cellular immunity
and is predisposed to M. leprae infection, and therefore, the
presence of the mycobacteria DNA in the oral mucosa of a
negative Mitsuda household contact will pose a greater risk
of acquiring leprosy when compared with a non carrier (neg-
ative DNA detection).
Our results suggest that endemic countries must maintain
a special surveillance programme for contacts, looking for
those with M. leprae DNA in buccal swabs, anti-PGL-1 ELISA
seropositivity, and a negative Mitsuda test [11,24]. This
molecular and immunological study of leprosy epidemiology
provides evidence of the oral mucosa as a secondary source
of infection and transmission of M. leprae, and the contacts
may be involved in the active transmission of bacilli in ende-
mic areas. Our results have great epidemiological relevance
and may lead to an additional and important strategy in lep-
rosy surveillance programmes, with a direct effect on pre-
vention and control of the disease.
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